Michael J Hadd

USPTO Granted Patents = 14 (Patent Applications = 7)

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 11)

Average Co-Inventor Count = 6.8

ph-index = 4

Forward Citations = 76(Granted Patents)

Company Filing History:

Ambit Biosciences Corporation

patents

Years Active: 2010-2018

Loading Chart...

14 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 9938261 - Heterocyclic compounds and methods of use thereof (2018-04-10),

2. 9452167 - Heterocyclic compounds and methods of use thereof (2016-09-27),

3. 9308207 - JAK kinase modulating compounds and methods of use thereof (2016-04-12),

4. 8952058 - Heterocyclic compounds and methods of use thereof (2015-02-10),

5. 8927711 - JAK kinase modulating compounds and methods of use thereof (2015-01-06),

6. 8802637 - Benzylbenzene derivatives and methods of use (2014-08-12),

7. 8633207 - Quinazoline compounds and methods of use thereof (2014-01-21),

8. 8575321 - Benzylbenzene derivatives and methods of use (2013-11-05),

9. 8349851 - JAK kinase modulating compounds and methods of use thereof (2013-01-08),

10. 8106021 - Benzylbenzene derivatives and methods of use (2012-01-31),

11. 7838499 - Benzylbenzene derivatives and methods of use (2010-11-23),

12. 7838498 - Benzylic glycoside derivatives and methods of use (2010-11-23),

13. 7803778 - Glucose transport inhibitors and methods of use (2010-09-28),

14. 7795228 - Spiroheterocyclic glycosides and methods of use (2010-09-14),

Title: Michael J Hadd: Innovator in Heterocyclic Compounds

Introduction

Michael J Hadd is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of heterocyclic compounds. With a total of 14 patents, his work has been instrumental in advancing treatments for various kinase-mediated diseases.

Latest Patents

Among his latest patents, Michael has developed heterocyclic compounds aimed at treating diseases mediated by CSF1R, FLT3, KIT, and PDGFRβ kinases. These patents also include pharmaceutical compositions that utilize these compounds and methods for their application. His innovative approach has the potential to impact the treatment landscape significantly.

Career Highlights

Michael has worked with notable companies such as Theracos, Inc. and Ambit Biosciences Corporation. His experience in these organizations has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Yuanwei Chen and Yan Feng. Their collaborative efforts have further enhanced the research and development of new pharmaceutical solutions.

Conclusion

Michael J Hadd's contributions to the field of heterocyclic compounds and his extensive patent portfolio underscore his role as a leading innovator in pharmaceutical research. His work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.